2 min read
China’s Supreme Court Upholds Semaglutide Patent for Novo Nordisk
China’s Supreme People’s Court upholds Novo Nordisk’s semaglutide compound patent, supporting IP protection.
3 min read
Over 600,000 Californians Risk Losing Access to GLP-1 Weight-Loss Drugs
California’s Medi-Cal will stop covering GLP-1 weight-loss drugs for weight-loss-only prescriptions, effective Jan. 1, 2026.
